Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

503
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
503
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

627
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
627
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

912
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
912
Pancreatic Juice and Secretion01:26

Pancreatic Juice and Secretion

3.7K
Pancreatic juice is a clear fluid produced by the pancreas, containing water, salts, sodium bicarbonate, and enzymes vital for digestion in the small intestine. It helps break down large molecules, facilitating nutrient absorption.
When acidic chyme from the stomach enters the duodenum, it triggers the release of secretin, a hormone that prompts pancreatic juice secretion. After a fatty meal, cholecystokinin, another hormone, stimulates gallbladder contraction and enhances enzyme-rich...
3.7K
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

1.1K
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
1.1K
Acute Pancreatitis I: Introduction01:27

Acute Pancreatitis I: Introduction

1.6K
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical home access in children with asthma: Association with asthma severity and sociodemographic factors.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

Comparison of Type 2 Diabetes Mellitus Management by an Ambulatory Care Pharmacist vs Usual Care in a Medically Underserved Population.

Journal of pharmacy practice·2026
Same author

Impact of a charitable medication program and social vulnerability index on clinical outcomes in uninsured adults with diabetes.

Journal of the American Pharmacists Association : JAPhA·2026
Same author

Analysis of US Pediatric Pharmacists Incomes: A Gender Comparison Survey Study by the Pediatric Pharmacy Association, Practice-Based Research Network.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same author

One Size May Not Fit All: A Case Series.

Pediatric pulmonology·2026
Same author

Epidemiology of pediatric abuse- and neglect-associated emergency department visits in the United States: an analysis of the 2019-2022 National Hospital Ambulatory Medical Care Survey.

Journal of osteopathic medicine·2026
Same journal

Uncovering Hidden Phenotypes of Bronchopulmonary Dysplasia: A Latent Class Analysis of Preterm Infants in a Middle-Income Setting.

Pediatric pulmonology·2026
Same journal

Early Structural Lung Changes in Primary Ciliary Dyskinesia (PCD).

Pediatric pulmonology·2026
Same journal

Agreement of Diaphragmatic Excursion Between Anterior Subcostal and Posterior Subcostal Ultrasonography in Premature Neonates.

Pediatric pulmonology·2026
Same journal

Efficacy and Safety of Biologic Therapies for Uncontrolled Asthma: An Overview of Systematic Reviews.

Pediatric pulmonology·2026
Same journal

Case Report: Pulmonary Leiomyoma in an Immunocompetent 14-Year-Old East Asian Male.

Pediatric pulmonology·2026
Same journal

Postural Influence on Ventilation Efficiency and Relationship With Oxygen-Enhanced MRI in Cystic Fibrosis.

Pediatric pulmonology·2026
See all related articles

Related Experiment Video

Updated: Apr 9, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.9K

Improving Pancreatic Function With Elexacaftor/Tezacaftor/Ivacaftor.

Madison Pranske1, Alizay Paracha2, Carson Loncarich3

  • 1Oklahoma State University College of Osteopathic Medicine, Tulsa, Oklahoma, USA.

Pediatric Pulmonology
|April 8, 2026
PubMed
Summary
This summary is machine-generated.

Elexacaftor/tezacaftor/ivacaftor (ETI) treatment shows potential for reversing pancreatic insufficiency in cystic fibrosis (CF) patients. Early ETI initiation and monitoring fecal elastase (FE-1) are crucial for improving pancreatic function.

Keywords:
cystic fibrosisfecal elastasepancreatic functionpediatric

More Related Videos

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing
06:59

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing

Published on: May 12, 2023

1.9K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

2.0K

Related Experiment Videos

Last Updated: Apr 9, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.9K
Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing
06:59

Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing

Published on: May 12, 2023

1.9K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

2.0K

Area of Science:

  • Medical Research
  • Pulmonology
  • Gastroenterology

Background:

  • Cystic Fibrosis (CF) leads to pancreatic cell dysfunction, necessitating enzyme replacement therapy.
  • Elexacaftor/tezacaftor/ivacaftor (ETI) is a novel treatment for CF.
  • The impact of ETI on pancreatic function in CF patients requires investigation.

Purpose of the Study:

  • To evaluate the effect of ETI treatment on pancreatic function in individuals with CF.
  • To determine if ETI can improve pancreatic enzyme levels (fecal elastase - FE-1).

Main Methods:

  • Retrospective analysis of CF Foundation Patient Registry data from the Tulsa CF Center.
  • Inclusion of individuals aged 0-21 years treated with ETI.
  • Collection of demographic data, FE-1 values, BMI percentiles, and CFTR mutation information.
  • Statistical analysis including descriptive statistics and Spearman Correlation.

Main Results:

  • Most patients on ETI (n=49) had severe pancreatic insufficiency post-treatment (79.6%).
  • A small percentage (10.2%) achieved pancreatic sufficiency post-ETI.
  • Early ETI initiation and homozygous F508del mutation were associated with improved pancreatic function.
  • Among 24 patients with pre- and post-ETI FE-1 values, 20.8% showed conversion to moderate or sufficient pancreatic status.

Conclusions:

  • ETI therapy may potentially reverse pancreatic insufficiency in CF patients.
  • Early initiation of ETI therapy is important for pancreatic function.
  • Standardized monitoring of FE-1 values is recommended to track treatment efficacy.